Comparison of the proliferative effects of ethinylestradiol on human breast cancer cells in an intermittent and a continuous dosing regime

Hormone and Metabolic Research

Volumn 40, Issue 3, 2008, Pages 206-209

  Merki Feld, G S ^a   Seeger, H ^b   Mueck, A O ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Breast cancer cells; Continuous incubation; Ethinylestradiol; Intermittent incubation; Proliferation

Indexed keywords

ETHINYLESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER RISK; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; HUMAN; HUMAN CELL; INCUBATION TIME; PRIORITY JOURNAL; BREAST TUMOR; CELL CULTURE; COMPARATIVE STUDY; DOSE RESPONSE; FEMALE; METABOLISM; NEOPLASM; PATHOLOGY;

BREAST NEOPLASMS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR CELLS, CULTURED;

EID: 43249119669     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1004540     Document Type: Article

References (23)

1. Russo IH, Russo J. The role of estrogen in breast cancer. In: Russo J, Russo IH (eds.) Molecular Basis of Breast Cancer Prevention Treatment. Heidelberg: Springer Verlag, 2005; 89-136
2. Fowke JH, Shu XO, Dai Q, Jin F, Cai Q, Gao YT et al. Oral contraceptive use and breast cancer risk: modification by NAD(P)H:quinone oxoreductase (NQO1) genetic polymorphisms. Cancer Epidemiol Biomarkers Prev 2004; 13: 1308-1315
3. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-1727
4. Althuis MD, Brogan DR, Coates RJ, Daling JR, Gammon MD, Malone KE et al. Hormonal content and potency of oral contraceptives and breast cancer risk among young women. Br J Cancer 2003; 88: 50-57
5. Kahlenborn C, Moduqno F, Potter DM, Severs WB. Oral contraceptive use as a risk factor for premenopausal breast cancer: a meta-analysis. Mayo Clinic Proc 2006; 81: 1290-1302
6. Den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception 1999; 59: 357-362
7. Sillem M, Schneidereit R, Heithecker R, Mueck AO. Use of an oral contraceptive containing drospirenone in an extended regimen. Eur J Contraception Reprod Health Care 2004; 8: 162-169
8. Sulak PJ, Cressman BE, Waldrop E, Holleman S, Kuehl TJ. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol 1997; 89: 179-183
9. Wiegratz I, Kuhl H. Long-cycle treatment with oral contraceptives. Drugs 2004; 64: 2447-2462
10. Schoonen WG, Joosten JW, Kloosterboer HJ. Effects of two classes of progestagens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells: I. MCF-7 cell lines. J Steroid Biochem Mol Biol 1995; 55: 423-437
11. Humpel M, Tuber U, Kuhnz W, Pfeffer M, Brill K, Heithecker R et al. Comparison of serum ethinyl estradiol, sex-hormone-binding globulin, corticoid-binding globulin and cortisol levels in women using two low-dose combined oral contraceptives. Horm Res 1990; 33: 35-39
12. Jeng MH, Parker CJ, Jordan VC. Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res 1992; 52: 6539-6546
13. Kloosterboer HJ, Schoonen WG, Deckers GH, Klijn JG. Effects of progestagens and Org OD14 in in vitro and in vivo tumor models. J Steroid Biochem Mol Biol 1994; 49: 311-318
14. Mueck AO, Seeger H, Wallwiener D. Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition. Climacteric 2003; 6: 221-227
15. Krämer EA, Seeger H, Krämer B, Wallwiener D, Mueck AO. The effects of progesterone, medroxyprogesterone acetate, and norethisterone on growth factor- and estradiol-treated human cancerous and noncancerous breast cells. Menopause 2005; 12: 468-474
16. Guengerich FP. Metabolism of 17 alpha-ethinylestradiol in humans. Life Sci 1990; 47: 1981-1988
17. Fortunati N, Catalano MG. Sex hormone-binding globulin (SHBG) and estradiol cross-talk in breast cancer cells. Horm Metab Res 2006; 38: 236-240
18. Timmer CJ, Apter D, Voortman G. Pharmacokinetics of 3-keto-desogestrel and ethinylestradiol released from different types of contraceptive vaginal rings. Contraception 1990; 42: 629-642
19. Lippert C, Seeger H, Wallwiener D, Mueck AO. Comparison of the effects of 17alpha-ethinylestradiol and 17beta-estradiol on the proliferation of human breast cancer cells and human umbilical vein endothelial cells. Clin Exp Obstet Gynecol 2002; 29: 87-90
20. Lippert C, Seeger H, Wallwiener D, Mueck AO. Comparison of the effects of continuous combined and sequential combined medroxyprogesterone acetate-estradiol treatment on the proliferation of MCF-7 cells. Climacteric 2000; 3: 271-277
21. Lippert C, Seeger H, Wallwiener D, Mueck AO. The effect of medroxyprogesterone acetate and norethisterone on the estradiol stimulated proliferation in MCF-7 cells: comparison of continuous combined versus sequential combined estradiol/progestin treatment. Eur J Gynaecol Oncol 2001; 22: 331-335
22. Seeger H, Wallwiener D, Mueck AO. The effect of progesterone and synthetic progestins on serum- and estradiol-stimulated proliferation of human breast cancer cells. Horm Metab Res 2003; 35: 76-80
23. Catherino WH, Jeng MH, Jordan VC. Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism. Br J Cancer 1993; 67: 945-952